CMS has announced a time-limited demonstration—called the Medicare GLP-1 Bridge—that will allow eligible Medicare beneficiaries to access certain GLP-1 medications for $50 per month beginning July 1, 2026 through December 31, 2027.
What’s included
CMS’ beneficiary guidance notes that, starting July 1, 2026, the Bridge will make available all formulations of Foundayo®, all formulations of Wegovy®, and the Zepbound® KwikPen® formulation (with the single-dose vial and single-dose pen formulations of Zepbound not included). CMS also notes the list may be updated over the course of the program.
How access works (high-level)
This is not an “agent enrollment” program. CMS indicates access will require the beneficiary’s provider to submit a prior authorization request and prescription for a use covered under the demonstration, and that prior authorizations will not be accepted or processed before July 1, 2026.
CMS also states beneficiaries do not need to register or opt in, and generally do not need to take action right now; more details will be provided prior to launch.
Important Part D and cost-sharing implications
CMS is explicit that Bridge coverage is outside the Part D benefit payment flow, with participating manufacturers providing eligible drugs at a $245 net price per monthly supply, while beneficiaries pay a $50 copay. CMS also states that neither the $245 nor the $50 copay counts toward Part D gross covered drug costs (GCPDC) or TrOOP, and that low-income cost-sharing subsidies do not apply to any portion of the copay.
Eligibility and “when the Bridge does NOT apply”
CMS frames the Medicare GLP-1 Bridge as focused on weight management use; beneficiaries prescribed GLP-1s for other diagnoses (including examples CMS lists such as type 2 diabetes and obstructive sleep apnea) are generally expected to access GLP-1s through the Part D benefit and are ineligible for the Bridge even if they otherwise meet clinical criteria.
CMS also notes some plan-type eligibility nuances (for example, certain SNPs and EGWPs are eligible; other plan types may not be unless also enrolled in a standalone PDP).
Broker takeaways
- Treat this as a CMS demonstration (not a carrier benefit) with fixed beneficiary copay ($50/month) for eligible Bridge access.
- Be ready to explain that Bridge fills do not accumulate toward TrOOP and do not interact with Part D phases the way typical Part D claims do.
- Encourage clients to speak with their prescribing provider—providers will be the ones submitting prior authorization requests, and CMS has said PAs will not be processed before July 1, 2026.
- Watch for CMS updates on prior authorization processes and beneficiary instructions as we approach launch.
We’ll continue monitoring CMS updates and will share practical talking points and workflow guidance as CMS releases more operational details.